Sign up
Pharma Capital

Q BioMed discovers two key biomarkers in study of pediatric nonverbal autism

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive Investors the New York-based biotech has made a "tremendous" discovery in the first two biomarkers for pediatric nonverbal autism.

Corin says this allows the company a greater chance of success in its clinical study for drug candidate QBM-001, as these new biomarkers clearly define the patient population.


View full QBIO profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.